What is OncoMethylome Sciences?
OncoMethylome Sciences operates at the intersection of genomics and clinical oncology, specializing in the development of advanced DNA gene methylation tests. The company's core value proposition lies in its ability to facilitate early cancer detection and provide actionable insights for personalized treatment pathways. By identifying specific epigenetic markers, their diagnostic solutions empower healthcare professionals to predict patient responses to therapy and assess the risk of recurrence with high precision. This focus on precision medicine positions the firm as a critical player in the shift toward data-driven cancer care, where diagnostic accuracy directly correlates with improved patient outcomes and reduced systemic healthcare costs.
How much funding has OncoMethylome Sciences raised?
OncoMethylome Sciences has raised a total of $21.9M across 2 funding rounds:
Share Placement
$12.1M
Grant
$9.7M
Share Placement (2007): $12.1M, investors not publicly disclosed
Grant (2009): $9.7M, investors not publicly disclosed
Key Investors in OncoMethylome Sciences
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for OncoMethylome Sciences?
With the recent influx of capital, OncoMethylome Sciences is well-positioned to accelerate its clinical validation programs and expand its commercial footprint. The strategic focus will likely shift toward securing regulatory approvals for its pipeline of diagnostic assays and deepening partnerships with major healthcare institutions. As the demand for non-invasive, high-sensitivity screening tools continues to rise, the company is expected to leverage its technological foundation to capture a larger share of the personalized medicine market. Future growth will depend on the successful integration of its methylation-based tests into standard clinical workflows, effectively bridging the gap between laboratory innovation and bedside application.
See full OncoMethylome Sciences company page
